Pharmaceuticals News and Research

RSS

Cybercitizen Health Europe

In today's world of fragmented media and channel mix, it is increasingly difficult to isolate the information sources used by consumers to research health information and inform healthcare decision making.

17 Apr 2007

Progen Pharmaceuticals announces positive results in PI-88 trial

Progen Pharmaceuticals Limited has announced the final stage 1 results of its Phase 2 trial of PI-88 in patients who had previously undergone surgical removal of liver cancer.

17 Apr 2007

Osprey Pharmaceuticals issued 3 U.S. patents

Osprey Pharmaceuticals Limited has announced that it has been granted three patents by the U.S. Patent Office.

17 Apr 2007

Pharma sales reps' productivity inhibited by unnecessary internal communication

According to a new study by pharmaceutical research and consulting firm Best Practices, LLC, pharma sales reps spend an average of 13.7 hours a week managing internal communication.

17 Apr 2007

Lilly and AACR tackle cancer together

Innovative and collaborative cancer research can be the catalyst to improving patient outcomes.

17 Apr 2007

Researchers induce cell death in leukemia

Researchers from the Virginia Commonwealth University Massey Cancer Center presented preclinical research at the American Association of Cancer Research's annual meeting suggesting the potential of a new combination treatment for chronic lymphocytic leukemia (CLL).

17 Apr 2007

FDA accepts Satraplatin NDA for priority review

Spectrum Pharmaceuticals has announced that the New Drug Application (NDA) for satraplatin has been accepted for priority review by the U.S. Food & Drug Administration (FDA).

17 Apr 2007

FDA accepts GPC Biotech's Satraplatin NDA

GPC Biotech AG has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the Company's New Drug Application (NDA) for satraplatin in combination with prednisone for patients with hormone-refractory prostate cancer (HRPC) whose prior chemotherapy has failed.

17 Apr 2007

Expression Genetics completes phase I trial of lead drug candidate, EGEN-001

Expression Genetics, Inc., has announced the completion of a Phase I clinical study evaluating the Company's lead drug candidate, EGEN-001.

17 Apr 2007

Peregrine's selective anti-VEGF antibodies shown to be as effective as Avastin

Peregrine Pharmaceuticals has reported that preclinical data presented at the Centennial Annual Meeting of the American Association for Cancer Research (AACR) showed that its monoclonal antibody 2C3, which selectively blocks vascular endothelial growth factor (VEGF) from binding to the second of the two VEGF receptors, demonstrates potent anti-cancer efficacy in a preclinical orthotopic model of pancreatic cancer.

17 Apr 2007

Too many of the world's poor still denied HIV drugs

According to a new report by the World Health Organization (WHO), UNAIDS and UNICEF, only 28% of the world's poor with HIV have access to the antiretroviral drugs that could save their lives.

17 Apr 2007

New chemical agent, MCP110, provides synergistic effect to standard drugs

Integrating the use of drugs targeted to specific cancer proteins into current chemotherapy regimens to improve the efficacy of systemic treatment is an important clinical goal at Fox Chase Cancer Center.

16 Apr 2007

Investigational cancer 17-AAG drug targets critical proteins

A drug under study to treat various cancers selectively kills cancer cells because of its affinity for a modified version of a critical heat shock protein they contain, researchers have found.

16 Apr 2007

Essential medicines for children

Following recommendations from the Expert Committee on Essential Medicines, the World Health Organization (WHO) will immediately begin work to create a medicines list specifically tailored to children's needs. A group of experts will meet in July 2007 to produce the first international list of medicines to tackle diseases with high mortality and morbidity rates in children.

16 Apr 2007

New drug therapy zaps hepatitis C in 12 weeks

Trials of new hepatitis C drug suggest sufferers could be cleared of the virus within 12 weeks of treatment.

16 Apr 2007

New device to test for proteins that play important role in human health and disease

A new technology developed at the University of Toronto is revealing biochemical processes responsible for diseases such as cystic fibrosis and could one day pave the way for pharmaceutical applications.

15 Apr 2007

Use of computer-assisted drug design in drug discovery

Metabasis Therapeutics has announced that on March 27, 2007 at the American Chemical Society 233rd National Meeting and Exposition in Chicago, Dr. M. Rami Reddy presented, "Use of Computer-Assisted Drug Design in Drug Discovery: Limitations and Advantages of Available Computational Methods."

15 Apr 2007

Lupin Pharmaceuticals receives FDA approval for Suprax

Lupin Pharmaceuticals has announced that the U.S. Food and Drug Administration (US FDA) has approved the company's application for Suprax (Cefixime for oral suspension 200mg/5ml).

15 Apr 2007

Intarcia Therapeutics announces results from study of injectable Omega Interferon plus Ribavirin for treatment of hepatitis C genotype-1

Intarcia Therapeutics has announced final results from a Phase 2 study of omega interferon with or without ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C.

15 Apr 2007

GlaxoSmithKline initiates study of PROMACTA in chronic idiopathic thrombocytopenic purpura

GlaxoSmithKline has announced the initiation of a global, open-label, single group trial that will assess the efficacy, safety and tolerability of PROMACTA (eltrombopag olamine) in patients previously treated for chronic idiopathic thrombocytopenic purpura (ITP).

15 Apr 2007